Canaccord analyst Susan Anderson noted Kenvue recieved a positive court ruling in a case where the judge issued an order to exclude the plaintiff’s expert opinions. Canaccord said this is the best-case scenario and a win for Kenvue and willl now allow the company turn its focus toward executing its strategy of recapturing market share, driving manufacturing and supply chain efficiency, and a focus on launching innovative products. Canaccord maintains its Buy rating and $27 price target on Kenvue shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KVUE:
- Citi opens ‘positive catalyst watch’ on Kenvue into Tylenol decision
- Kenvue price target raised by $2 at Citi, here’s why
- Notable open interest changes for December 8th
- Kenvue Inc call volume above normal and directionally bullish
- Kenvue Inc put volume heavy and directionally bearish
Questions or Comments about the article? Write to editor@tipranks.com